



704.CELLULAR IMMUNOTHERAPIES: EARLY PHASE AND INVESTIGATIONAL THERAPIES |
NOVEMBER 28, 2023

Cytokine Profile Following Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies in the First-in-India Industry Phase-2 Study (IMAGINE)

Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Pankaj Malhotra, Sudeshna Dhar, Sandeepa Shetty, Mani Bharathi T.I., Anne Roshan Joseph, Gowri Shankar Krishnan, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Rahul Nahar, Lakshmikanth Gandikota, Anil Kamat



Blood (2023) 142 (Supplement 1): 6862.

<https://doi.org/10.1182/blood-2023-181585>



Split-Screen



Share 



Tools 

Background: Varnimcabtagene autoleucel (Var-cel, IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for patients (pts) with relapsed and/or refractory B cell malignancies. This abstract evaluates the cytokine profile and its correlation with safety outcomes and CAR-T expansion following var-cel infusion.

Methods: Serum was collected pre-infusion and upto 13 timepoints post infusion as per study schedule for evaluating cytokine levels. Nine cytokines (IFN-g, TNF- α , IL-1 β , IL-2, IL-7, IL-8, IL-10, IL-15 and MCP-1) were measured using a multiplexed kit on the Magpix platform. IL-6 level was measured using electrochemiluminescence immunoassay (ECLIA). Safety and adverse event data were collected for analysis along with measuring various cytokine levels in the serum. CAR-T persistence post infusion was monitored using ddPCR.

Results: 24 patients (pts) were infused with var-cel in the IMAGINE study. Var-cel levels in peripheral blood post-infusion were measured at multiple timepoints for all infused pts using ddPCR platform. The var-cel levels peaked (Tmax) at a median of 10 days post infusion (D+10; range: 10 - 28 days) with median Cmax of 125,242 (range 18,256 - 413,968 copies/ μ g genomic DNA). The median duration of persistence was 56 days with persistent CAR seen in 3 pts at last follow-up.

[Skip to Main Content](#)

Adverse events of special interest (AESIs) reported were CRS (Grade [G] 1 62.5%; G3+ 4.2%; overall 66.7%) and ICANS (G1 4.2%; G3+ 0%; overall 4.2%). The median onset of CRS at D+5, 5 days before the median var-cel Tmax of D+10. The median duration for CRS was 3 days. No G3+ ICANS was reported.

Serum IL-6 levels peaked at a median of D+7 post infusion and reached above 40 pg/mL for 13 pts, all of whom experienced CRS. All eight pts with no CRS had peak IL-6 levels below 40 pg/mL. Despite this significant association with CRS ($p < 0.001$, Man-Whitney test) and published causation, IL-6 level peaked towards the end of clinical course of CRS manifestation, but usually at or before peak var-cel expansion (Tmax). Interestingly, the increase in IL-6 levels tended to begin early and persist longer for some B-NHL patients compared to B-ALL patients.

Preliminary multiplexed cytokine analysis for evaluated pts ($n=6$) indicated that IFN- γ , TNF- α , IL-1 β , IL-2, IL-7, IL-8 remained within published physiological limits for most patients at all timepoints (except one pt with highest levels at screening). One patient showed mild increase in IFN- γ (peak 50.88 pg/mL) and two pts showed mild increase in IL-8 around D+4 to D+7 (peak 47.71 pg/mL). IL-15 and MCP-1 levels were relatively higher (>2 fold) from D0 to D+7 post infusion, compared to the screening timepoint, consistent with the duration of CRS. Only IL-10, an anti-inflammatory and cytokine synthesis inhibitory factor stood out having a sharp peak (median: 230 pg/mL) for all six patients at D+4 to D+10, consistent with the timeline for end of CRS and before var-cel Tmax. Occasional pt with no clinical CRS also showed IL-10 peak. Updated cytokine profile data shall be presented at the meeting.

Conclusions: This is the first-in-India industry study evaluating cytokine profile at multiple timepoints before and after var-cel infusion and its correlation with clinical CRS. As per published literature, IL-6 levels were significantly associated with clinical CRS and showed association with peak var-cel expansion. There was a sharp increase in both IL-6 and IL-10 levels in serum post infusion, concurrent with clinical CRS prior to peak var-cel expansion. A further detailed study of cytokine profile following var-cel infusion shall help prognosticate safety outcomes.

Disclosures

Dhar:*Immuneel Therapeutics Private Limited*: Current Employment. **Shetty:***Immuneel Therapeutics Private Limited*: Current Employment. **T.I.:***Immuneel Therapeutics Private Limited*: Current Employment. **Joseph:***Immuneel Therapeutics Private Limited*: Current Employment.

Krishnan:*Immuneel Therapeutics Private Limited*: Current Employment. **Arasu:***Immuneel Therapeutics Private Limited*: Current Employment. **Elluru:***Immuneel Therapeutics Private Limited*: Current Employment. **Akheel:***Immuneel Therapeutics Private Limited*: Current Employment.

Nahar:*Immuneel Therapeutics Private Limited*: Current Employment. **Gandikota:***Immuneel Therapeutics Private Limited*: Current Employment. **Kamat:***Immuneel Therapeutics Private Limited*: Current Employment.

[Skip to Main Content](#)

Figure 1






Figure 1. Cytokine profile of patients after varicel infusion: (A) Serum IL-6 levels at different timepoints for 24 patients – line plots with CRS events on left and heatmap on right. 'Scr' is screening timepoint and D0 is day infusion begins. White colour in heatmap indicates 40 pg/mL, blue is below it and red is above it. Grey indicates absence of data.

(B) Line plots and heatmaps depicting levels of nine other cytokines (IFN- γ , TNF- α , IL-1 β , IL-2, IL-7, IL-8, IL-10, IL-15 and MCP-1) in 6 patients evaluated at different timepoints, using multiplexed assay. Symbols and colours for the 6 patients are same in all line plots, as shown for MCP-1. Blue-white colour in heatmap indicates published physiological range (healthy subjects) and red is above it.

[VIEW LARGE](#)
[DOWNLOAD SLIDE](#)
[Sign in via your Institution](#)
[Add comment](#)

Volume 142, Issue Supplement 1

November 2 2023

[< Previous Article](#)
[Next Article >](#)
[Skip to Main Content](#)
